Back to top

http://widget3-stage.zacks.com/microcap/is_microcap_ticker/json/PACB
more

data://text/plain;base64,UEFDQg==
http://quote-feed-stage.zacks.com/PACB
http://widget3-stage.zacks.com/stocks/data/json/PACB
http://widget3-stage.zacks.com/quote/scorecard/json/PACB
http://widget3-stage.zacks.com/stocks/data/json/PACB

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.36 USD

1.36
6,082,673

-0.05 (-3.21%)

Updated Aug 31, 2026 04:00 PM ET

After-Market: $1.35 -0.01 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks


http://widget3-stage.zacks.com/archive/text/json/1/UEFDQg==

Zacks News

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Pacific Biosciences of California (PACB) concluded the recent trading session at $1.97, signifying a -5.74% move from its prior day's close.

Zacks Equity Research

Pacific Biosciences of California (PACB) Stock Moves -4.04%: What You Should Know

by Zacks Equity Research

Pacific Biosciences of California (PACB) reached $1.9 at the closing of the latest trading day, reflecting a -4.04% change compared to its last close.

Zacks Equity Research

PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations

by Zacks Equity Research

PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.

Zacks Equity Research

Pacific Biosciences of California (PACB) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.59, marking a -1.85% move from the previous day.

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.

Zacks Equity Research

PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell

by Zacks Equity Research

PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.

Zacks Equity Research

Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

by Zacks Equity Research

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.52, marking a +2.01% move from the previous day.

Zacks Equity Research

PacBio Enters Carrier Screening Market With PureTarget Expansion

by Zacks Equity Research

PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.

Zacks Equity Research

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.29, indicating a +1.57% shift from the previous trading day.

Zacks Equity Research

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

by Zacks Equity Research

In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.17, denoting a -7.14% move from the preceding trading day.